跳至主要内容
临床试验/NL-OMON37009
NL-OMON37009撤回2 期

Treatment of Complex Regional Pain Syndrome type 1: A randomized placebo controlled double-blind study with ARA 290, The CRPSARA Study - Treatment of CRPS with ARA290

eids Universitair Medisch Centrum0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
撤回
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Inclusion criteria will be the *Budapest Criteria* for CRPS1. These criteria have a high specificity and sensitivity for the diagnosis of the disease [1]. The criteria are:
  • (1) Continuing pain, which is disproportionate to any inciting event;
  • (2) Must report at least one symptom in three of the four following categories:
  • a. Sensory: reports of hyperesthesia and/or allodynia;
  • b. Vasomotor: reports of temperature asymmetry and/or skin color changes and/or color asymmetry;
  • c. Sudomotor/edema: reports of edema and/or sweating changes and sweating asymmetry;
  • d. Motor/trophic: reports of decreased motor ranges and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin);
  • (3) Must display at least one sign at time of evaluation in two or more of the following categories:
  • a. Sensory: hyperalgesia (to pinprick) and/or allodynia (to light touch and/or deep somatic pressure and/or joint movement);
  • b. Vasomotor: evidence of temperature asymmetry and/or skin color changes and/or color asymmetry;
  • c. Sudomotor/edema: evidence of edema and/or sweating changes and sweating asymmetry;
  • d. Motor/trophic: evidence of decreased motor ranges and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin);
  • (4) There is no other diagnosis that better explains the signs and symptoms.
  • (5) Pharmacotherapy for CRPS symptoms (e.g., analgesics, antidepressants, and/or anticonvulsants ) has been stable for at least 4 weeks

排除标准

  • Exclusion criteria are:
  • * Inability to give informed consent;
  • * Patients suffering from other pain syndromes;
  • * Clinically relevant abnormal history of physical and mental health, as determined by medical history taking and physical examinations obtained during the screening visit and/or prior to the administration of the initial dose of the study drug (as judged by the investigator);
  • * A semi recumbent systolic blood pressure of >160 mmHg and/or diastolic blood pressure of > 95 mmHg at screening;
  • * History of alcoholism or substance abuse within three years prior to screening;
  • * Positive pregnancy test or lactation
  • * Male subjects habitually using more than 21 units of alcohol per week and female subjects using more than 14 units of alcohol per week;
  • * Subject has a history of severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food;
  • * Subjects that received a vaccination or immunization within the last month;
  • * Participation in an investigational drug trial in the 3 months prior to administration of the initial dose of study drug or more than 4 times per year;
  • * Subject has undergone major surgery within three months prior to screening;
  • * Inability or unwillingness to self-administer ARA 290 via subcutaneous injections
  • * Any other condition that in the opinion of the investigator would complicate or compromise the study, or the well being of the subject

研究者

相似试验